

**MICROCAP GROWTH****Portfolio Comments****June 30, 2025****Distinguishing Features**

GIM builds the [Microcap Growth](#) portfolio from the bottom-up; sector weightings are secondary to stock selection. The Microcap Growth strategy maintained an overweight position in Information Technology, Consumer Discretionary, and Health Care. The portfolio is equal weight the benchmark in Industrials and Energy and underweight in all other sectors. The portfolio has no exposure to Utilities, Real Estate and Communication Services.

**Market Environment**

In early April, the Trump Administration introduced a new wave of tariff measures that initially unsettled markets and investors alike. Branded as “Liberation Day,” the tone and substance of the announcement raised concerns about potential trade disruptions and broader macroeconomic implications. This policy shift triggered a spike in volatility and increased risk aversion, particularly among growth-oriented stocks.

At the Berkshire Hathaway Annual meeting in early May 2025, Warren Buffett remarked, “*People have emotions, but you got to check them at the door when you invest.*” His words served as a timely reminder of the importance of emotional discipline during turbulent markets. Despite heightened uncertainty, these dislocations also created compelling opportunities especially in underfollowed areas of the market where long-term secular tailwinds remain intact and valuations diverged from fundamentals.

A series of transformative Executive Orders issued by the Administration during the quarter reignited investor optimism. These policies reduced regulatory friction, accelerated approval timelines, and signaled strong federal support for several high-growth sectors, including artificial intelligence (AI), eVTOL aircraft and next-generation nuclear power.

Meanwhile, sentiment toward biotechnology improved as key regulatory overhangs began to ease. The newly confirmed FDA Commissioner reaffirmed the agency’s commitment to accelerating drug approval timelines, while the newly appointed head of CBER (Center of Biologics Evaluation and Research) reiterated ongoing regulatory support for innovation in cell and gene therapy, helping to restore confidence across the sector.

**Performance Discussion**

For the second quarter of 2025, the Granahan Microcap Growth strategy returned 25.8%, outperforming the Russell Microcap Growth Index return of 20.9%. Stock selection in the Healthcare sector added alpha, even as the sector delivered only modest overall returns. With regards to Life Cycles this quarter, Pioneers and Special Situations outperformed the benchmark while Core Growth names underperformed the benchmark.

Top Contributors	Top Detractors
1. <b>Centrus Energy Corp.</b> (Energy, Special Situation)	1. <b>Syndax Pharma.</b> (Health Care, Pioneer)
2. <b>Core Scientific</b> (Info Tech, Special Situation)	2. <b>OrthoPediatrics, Corp.</b> (Health Care, Core Growth)
3. <b>Stoke Therapeutics</b> (Health Care, Pioneer)	3. <b>CEVA, Inc.</b> (Info Technology, Special Situation)
4. <b>Enovix Corp.</b> (Info. Tech, Pioneer)	4. <b>PROS Holdings, Inc.</b> (Info Tech, Special Situation)
5. <b>Taysha Gene Therapies</b> (Health Care, Pioneer)	5. <b>Pursuit Attractions &amp; Hospitality</b> Cons Disc, Special Sit



### Top Contributors in Q2:

- **Centrus Energy (LEU)** is a nuclear fuel supplier specializing in advanced enrichment technologies critical to supporting next-generation reactors and national energy security. The stock gained momentum in Q2 following a Trump Administration's Executive Order, which included accelerated licensing pathways and federal support for domestic nuclear fuel production. As a strategic beneficiary of this policy shift, Centrus stands to play a central role in reshoring America's nuclear fuel supply chain. We initiated a position early in the quarter and the stock has since delivered strong performance as investors recognized its unique positioning in a revitalized U.S. nuclear ecosystem.
- **Core Scientific (CORZ)** has transitioned from a cryptocurrency miner to an AI infrastructure provider, focusing on high-density colocation services for enterprise-scale compute. During Q2, the stock surged after reports of renewed acquisition talks with CoreWeave. The stock remains attractive given its position in AI infrastructure development either as an acquisition candidate or standalone company.
- **Stoke Therapeutics (STOK)** is a clinical-stage biotech company pioneering RNA-based therapies to restore protein production in rare genetic diseases most notably targeting Dravet syndrome. A key growth driver this quarter was its collaboration with Biogen alongside progression into Phase 3 trials which reinforced commercial confidence. With execution underway and strong financial backing, we believe Stoke remains well positioned for further upside based on upcoming clinical and milestone catalysts.
- **Enovix Corporation (ENVX)** is a company focused on a next-generation battery technology designed for improved energy density, rapid charging, and industry-leading safety. The stock responded favorably to the successful launch of its proprietary silicon-anode platform signaling Enovix's ability to commercialize its advanced technology. With a solid cash position, expanding manufacturing footprint, and accelerating customer adoption, we believe ENVX stands well positioned for further growth as it scales production and executes on its commercialization roadmap.
- **Taysha Gene Therapies (TSHA)** is a clinical-stage biotech focused on developing a gene therapy for Rett syndrome, a rare neurodevelopmental disorder with no approved treatments. In 2Q25, the stock reacted positively as the company secured FDA alignment on its pivotal trial design that enabled a streamlined, single-arm study with regulatory clarity and no formal end-of-phase meeting required. Additionally, positive early results from the REVEAL trial further reinforced investor confidence. With a clear path to trial initiation in Q3 and strong tailwinds behind the regulatory strategy, we believe TSHA is well positioned as a high-conviction gene therapy investment.

### Top Detractors in Q2:

- **Syndax Pharmaceuticals (SNDX)** is a commercial-stage biotech focused on treating hematologic cancers with its FDA-approved therapies Revuforj and Niktimvo. The stock performed poorly due to investor concerns about the long-term market opportunity and the potential for increased competition. The company delivered strong Revuforj revenue early in its launch well ahead of expectations and increases our confidence in the outlook. We increased our position due to Syndax's robust pipeline, strong strategic partnerships, and upcoming catalysts such as the mNPM1 supplemental NDA and Phase 3 trial updates that make it a compelling biotech investment.
- **OrthoPedic (KIDS)** is the only pure-play orthopedic device company focused exclusively on pediatric care, supplying innovative implants and instruments to leading children's hospitals in the U.S. and



internationally. While the company has been delivering inline financial results, investor apathy has weighed on this stock and other small cap medical device companies. We believe the stock is attractive given its market leadership in a growing pediatric orthopedics market, a strong balance sheet and compelling valuation relative to its long-term growth trajectory.

- **CEVA Inc. (CEVA)** is a leading licensor of silicon and software IP that powers smart-edge devices like modems and Wi Fi connectivity devices. For 1Q results, CEVA reported strong licensing agreements; however, royalty income missed expectations primarily due to a slowdown in shipments from a key Chinese mobile partner. We view this slowdown as a timing issue and added to our position during Q2. We believe CEVA's exposure to accelerating AI-related semiconductor content and its leadership in connectivity IP position it well for robust royalty growth and renewed earnings tailwinds going forward.
- **PROS Holdings (PRO)** is a leading provider of AI-powered SaaS solutions focused on pricing optimization and revenue management systems for enterprise clients. The stock underperformed during the quarter due to uncertainty surrounding enterprise IT spending especially given the company's exposure to travel-related industries. There have also been some recent changes in the executive suite that have led to uncertainty. We remain confident in sustained subscription growth and view PRO's ongoing AI-driven innovation in pricing intelligence creating a compelling long-term growth opportunity.
- **Pursuit Attractions & Hospitality (PRSU)** operates a collection of 15 destination attractions and 28 lodges across the U.S., Canada, and Iceland offering travelers immersive experiences in iconic natural and cultural settings. The company reported a slight revenue miss in the first quarter, but robust advanced bookings give us confidence in the outlook for the balance of the year. The stock pulled back in Q2 amid broader leisure-sector headwinds and cap ex needs tied to its growth strategy, but we view the weakness as an attractive entry point. With a clean balance sheet post divestiture of a non-core business, we have increased confidence in the compelling runway for growth in a differentiated leisure/hospitality franchise.

## Outlook

As we enter the third quarter, recession fears have abated, interest rates have stabilized, and the evolving tariff landscape is coming into focus. The Trump Administration has taken assertive steps to advance its economic agenda, including regulatory rollbacks that could accelerate activity in key areas such as U.S. reshoring, infrastructure modernization, and industrial technology advancement. For high-quality, innovation-driven small caps, this environment offers a compelling setup, and we believe the current landscape favors active managers positioned to identify and invest in companies executing well through the volatility. At the same time, we remain attentive to potential disruptions that could impact the markets including evolving tariff policies, ongoing geopolitical tensions, and signs of renewed economic uncertainty. We continue to monitor these developments closely and maintain a fundamental-driven approach to risk management across the portfolio.

Our portfolio holdings reflect high-conviction themes such as AI infrastructure, industrial automation, and biotechnology innovation. Our investment approach remains disciplined and focused on companies with strong balance sheets, durable competitive advantages, and exposure to powerful secular trends that we believe will drive attractive, long-term returns.



*Disclosure: The information provided in this commentary should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. All performance attribution is calculated using gross of fees returns and should be considered approximate.*

*It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.*